Definium Therapeutics (DFTX) Shares Outstanding (Diluted Average) (2021 - 2025)

Definium Therapeutics (DFTX) has 5 years of Shares Outstanding (Diluted Average) data on file, last reported at $89.3 million in Q4 2025.

• Shares Outstanding (Diluted Average) for Q4 2025 came in at $89.3 million, up 26.78% year-over-year; the trailing twelve-month figure through Dec 2025 was $89.3 million (up 26.78% YoY), and the FY2025 annual result was $89.3 million, up 26.78% from the prior year.
• Shares Outstanding (Diluted Average) grew to $89.3 million in Q4 2025 per DFTX's latest filing, from $70.5 million in the prior quarter.
• Over five years, Shares Outstanding (Diluted Average) peaked at $400.3 million in Q2 2021 and troughed at $27.1 million in Q3 2021.
• A 5-year average of $68.1 million and a median of $38.9 million in 2023 frame the typical range for Shares Outstanding (Diluted Average).
• The sharpest annual moves came in 2022 and 2024: Shares Outstanding (Diluted Average) slumped 92.95% in 2022, then soared 102.01% in 2024.
• A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $27.4 million in 2021, then increased by 12.71% to $30.9 million in 2022, then rose by 26.9% to $39.2 million in 2023, then jumped by 79.94% to $70.5 million in 2024, then rose by 26.78% to $89.3 million in 2025.
• Business Quant data shows DFTX's Shares Outstanding (Diluted Average) at $89.3 million in Q4 2025, $70.5 million in Q4 2024, and $80.2 million in Q3 2024.